Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). These data underscore the company's commitment to developing treatments to improve the lives of patients with cancer.

"Through our commitment to R&D and collaborations with the scientific and patient communities, we continue to bring targeted treatments to patients living with cancer and other diseases for which there is an unmet need," said Hervé Hoppenot, President, Novartis Oncology. "Our broad and deep portfolio of development programs gives us multiple opportunities to further advance treatments for the millions of patients and their families affected by these diseases."

Highlighted at the ASCO meeting, taking place from June 3 - 7 in Chicago, will be results from key Phase III studies on Novartis products and compounds, including a trial on adjuvant treatment with Gleevec® (imatinib mesylate) tablets* in patients following resection of KIT (CD117)-positive gastrointestinal stromal tumors (GIST) featured at the plenary session on June 5, and two pivotal studies of the Janus kinase (JAK) inhibitor, INC424 (ruxolitinib), in patients with myelofibrosis on June 6(1). In addition, a study of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), showing patients on Tasigna® (nilotinib) 150 mg capsules are less likely to develop mutations than those taking Gleevec, will be presented on June 6(1).

Also featured at the Annual Congress will be results from two sub-analyses of the landmark Medical Research Council Myeloma IX clinical trial comparing the effect of Zometa® (zoledronic acid) Injection versus clodronate, on overall survival, progression-free survival and skeletal-related events when used with
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MADISON, N.J., July 24, 2014 , ... prior year , Adjusted diluted EPS from continuing operations ... diluted EPS from continuing operations of $0.92, 7% below prior ... 34% versus prior year , Full year 2014 revenues ... 2% to 4% previously , Full year 2014 adjusted ...
(Date:7/24/2014)... July 24, 2014 MedVantx, Inc., the ... prescription delivery channel in physician offices, MedStart Connect, ... issues related to medication non-adherence and hospital readmission ... recent issue of the Annals of ... reported that frequent changes in generic medication pill ...
(Date:7/24/2014)... VANCOUVER, British Columbia , July 24, 2014 /PRNewswire/ ... announced today that the Company,s second quarter 2014 financial ... and that the Company will host a conference call ... Management will provide an overview of the company,s financial ... To access the webcast, log on to ...
Breaking Medicine Technology:Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Medication Non-Adherence Issue Highlighted in Annals of Internal Medicine Study Could Be Eliminated by a New Direct-to-Consumer Delivery Channel Ensuring Consistent Medication Appearance 2Medication Non-Adherence Issue Highlighted in Annals of Internal Medicine Study Could Be Eliminated by a New Direct-to-Consumer Delivery Channel Ensuring Consistent Medication Appearance 3OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014 2
... NEW YORK, Oct. 16 Reportlinker.com announces that ... its catalogue. , Reportlinker Adds Allergan ... http://www.reportlinker.com/p0155102/Reportlinker-Adds-Allergan-Inc-PharmaVitae-Profile.html , Introduction , This analysis ... in the Rx pharmaceutical sector. The profile encompasses ...
... Oct. 16 Reportlinker.com announces that a new ... , Reportlinker Adds Global Top 10 ... , http://www.reportlinker.com/p0155125/Reportlinker-Adds-Global-Top-10-Chemical-Companies----Industry-Financial-and-SWOT-Analysis.html ... Report: Strategic evaluation of industry and key players, ...
Cached Medicine Technology:Reportlinker Adds Allergan Inc.: PharmaVitae Profile 2Reportlinker Adds Allergan Inc.: PharmaVitae Profile 3Reportlinker Adds Allergan Inc.: PharmaVitae Profile 4Reportlinker Adds Allergan Inc.: PharmaVitae Profile 5Reportlinker Adds Allergan Inc.: PharmaVitae Profile 6Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis 2Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis 3Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis 4Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis 5
(Date:7/24/2014)... 24, 2014 Catholic Health Partners (CHP), ... Partners, has changed its name to Mercy Health. The ... to one unified team, focused on high-quality care, increased ... largest health system and fourth-largest employer. , “Our new ... are working together to improve the health of the ...
(Date:7/24/2014)... 2014 In response to a ... patients may benefit from parathyroidectomy, Dr. Babak Larian ... Beverly Hills today commented on hyperparathyroidism, a commonly ... misdiagnosed because its symptoms are vague and similar ... who have been diagnosed with fibromyalgia may actually ...
(Date:7/24/2014)... Discount-Dress.com, an innovative company that provides ... outfits, is doing its best to attract new clients. ... rates, up to 75% off. Recently, the company has ... Also, it has unveiled many new products for ladies ... lace wedding dresses, purple prom dresses and so forth. ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 6 Minutes ... kicking its metabolism into high gear with only a ... changes to one’s diet or lifestyle. This has caught ... review. , “Our 6 Minutes to Skinny review ... taken the time to understand exactly how your body ...
(Date:7/24/2014)... A new report from the Centers ... doctors in the U.S. have upgraded to electronic health records, ... to be embracing more digital options. Online healthcare networks now ... past patient histories, the latest published studies, or even allowing ... report from the Robert Wood Johnson Foundation last year found ...
Breaking Medicine News(10 mins):Health News:HMHP’s Parent, Catholic Health Partners, Changes Name to Mercy Health 2Health News:HMHP’s Parent, Catholic Health Partners, Changes Name to Mercy Health 3Health News:HMHP’s Parent, Catholic Health Partners, Changes Name to Mercy Health 4Health News:Is Hyperparathyroidism Misdiagnosed as Fibromyalgia? 2Health News:Is Hyperparathyroidism Misdiagnosed as Fibromyalgia? 3Health News:Discount-Dress.com Announces the Launch of Its New Blog and Publishes Articles About Its Fabulous Special Occasion Dresses 2Health News:6 Minutes to Skinny: Review Examining Craig Ballantyne’s Weight Loss Program Released 2Health News:6 Minutes to Skinny: Review Examining Craig Ballantyne’s Weight Loss Program Released 3Health News:Doctors Embracing Changing Technologies, And Technology Brings Options to Treatment 2Health News:Doctors Embracing Changing Technologies, And Technology Brings Options to Treatment 3
... has forged a,national partnership with Susan G. Komen ... Power to Keep Going(R)-to more than 1.5 million,breast ... http://www.newscom.com/cgi-bin/prnh/20071004/AQTH013 ) Officials with both organizations ... Energizer is the battery known around the world ...
... Join Men,s Health Network & Former Governor Gary ... SEATTLE, Oct. 4 Men,s Health Network,American Cancer ... physicians, key thought leaders, community organizations, and,policy makers ... in Washington,State. Among presenters will be Former Washington ...
... Malaria drug and vaccine research is booming. According to a ... The George Institute for International Health, 16 new malaria vaccine ... are about to reach the market; and by 2011 we ... , However, this unprecedented level of malaria R&D ...
... a valuable role in assessing people held in police ... and improving response times, according to research published in ... the University of Wolverhampton, UK, analysed just under 9,000 ... interviewed 31 custody nurses, custody officers and Forensic Medical ...
... Computer Sciences,Corporation (NYSE: CSC ) announced today ... the Centers for Medicare and Medicaid Services (CMS) ... Systems Development,program. The total ceiling value of the ... a one-year base,period and nine one-year options, is ...
... Across ... Five Hospitals in Abu Dhabi, HATBORO, Pa., ... of mobile enterprise solutions for the,healthcare and commercial industries, announced ... Services, in partnership with ITQAN, a,major systems integrator for businesses ...
Cached Medicine News:Health News:Energizer Joins Roster of Susan G. Komen Race for the Cure(R) National Sponsors; Energizer(R) ReTreat Pampers Cancer Survivors With Traveling Mini-Spa 2Health News:Energizer Joins Roster of Susan G. Komen Race for the Cure(R) National Sponsors; Energizer(R) ReTreat Pampers Cancer Survivors With Traveling Mini-Spa 3Health News:Washington Comes Together to Promote Smoking Cessation 2Health News:Malaria product portfolio would benefit from greater cohesion amongst stakeholders 2Health News:Malaria product portfolio would benefit from greater cohesion amongst stakeholders 3Health News:Nurses play a key role in police custody suites, complementing the traditional role of doctors 2Health News:Nurses play a key role in police custody suites, complementing the traditional role of doctors 3Health News:CSC Wins Enterprise System Development Contract From Centers for Medicare and Medicaid Services 2Health News:InfoLogix Signs Largest International Deal to Date with Healthcare Solutions Agreement in United Arab Emirates 2Health News:InfoLogix Signs Largest International Deal to Date with Healthcare Solutions Agreement in United Arab Emirates 3
This table provides the user with a moderatelypriced, yet fully versatile, electric table which will accept most HAAG-STREIT instruments as well as many of those from other ophthalmic manufacturers....
An antegrade femoral nail....
... Quad 4™ Intramedullary Nailing System was to ... used for the widest possible variety of ... were to minimize the number of implants ... system that could address antegrade or retrograde ...
... Xerox Copier Assistant software enables users who ... or have limited dexterity, to access and ... This software increases user productivity by leveraging ... interface, embedded text-to-speech software, and keyboard navigation ...
Medicine Products: